Sight Sciences Presentation at Morgan Stanley Conference
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care. The Company announced its participation at the upcoming Morgan Stanley Global Healthcare Conference.
Event Details
Sight Sciences' management is scheduled to present on an upcoming date. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company’s website.
About Sight Sciences
Sight Sciences is committed to transforming care and improving patients’ lives through innovative eyecare technology. The Company employs minimally invasive and non-invasive methods to address the underlying causes of prevalent eye diseases, striving to establish more effective treatment paradigms.
Innovative Technologies
The Company’s OMNI Surgical System is an implant-free glaucoma surgery technology developed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. It is CE Marked for additional procedures in treating open-angle glaucoma. The SION Surgical Instrument is designed for ophthalmic surgeries to excise trabecular meshwork effectively.
TearCare System
Sight Sciences also offers the TearCare System, which is cleared in the United States for localized heat therapy to address evaporative dry eye disease due to meibomian gland dysfunction (MGD). This system allows physicians to clear gland obstructions, targeting a leading cause of dry eye disease.
Investor and Media Contacts
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
Frequently Asked Questions
What is the purpose of Sight Sciences' presentation at the conference?
The presentation is to showcase the Company's innovative eyecare technologies and advancements in the field.
What technologies does Sight Sciences focus on?
The Company develops interventional technologies for treating glaucoma and dry eye diseases.
How does the OMNI Surgical System work?
The OMNI Surgical System is designed for implant-free glaucoma surgery to reduce intraocular pressure.
Is the TearCare System widely available?
Yes, the TearCare System is 510(k) cleared for use in the United States.
Who can be contacted for more information about investors and media?
For investor inquiries, contact Philip Taylor at Gilmartin Group, and for media inquiries, contact the Company's PR team.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.